Explore evidence-based strategies to achieve optimal LDL-C targets and reduce vascular events. This update outlines ESC-endorsed goals, timing, and combination therapies—including statins, ezetimibe, and PCSK9 inhibitors – to guide clinical decision-making in managing lipid levels for high-risk individuals.

Obesity and ageing don’t just add to cardiovascular risk individually — together, they accelerate it. This article explores how overlapping biological mechanisms like inflammation and oxidative stress link the two, and how weight reduction and new metabolic therapies may offer powerful, dual-action benefits. Learn why personalised strategies are the future of cardiometabolic care in an ageing, increasingly obese world.

Explore three standout studies from ACC 2025 that are reshaping heart failure management — from fluid restriction debates to game-changing therapies like dapagliflozin and IV iron. A must-read for clinicians staying ahead in cardiovascular care.

A UK Biobank study of nearly 12,000 people with T2D shows that each additional risk factor controlled—such as BMI, blood pressure, LDL, or HbA1c—lowers heart failure risk by an average of 19%. Those with optimal control of six or more risk factors saw a 67% lower risk and HF-free survival comparable to non-diabetic participants.